Anti-NMDA receptor encephalitis epidemiology and demographics: Difference between revisions
(Created page with "__NOTOC__ {{Anti-NMDA receptor encephalitis}} {{CMG}} ==Overview== ==Epidemiology and Demographics== ==References== {{Reflist|2}} Category:Needs content Category:Rheu...") |
|||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Anti-NMDA receptor encephalitis}} | {{Anti-NMDA receptor encephalitis}} | ||
{{CMG}} | {{CMG}}; AE {{DMakkar}} | ||
==Overview== | ==Overview== | ||
Encephalitis has an annual incidence of 2-3 per 100,000, with 40% being infectious, 40% of unknown cause, and 20% immune-mediated. Anti-NMDA receptor encephalitis and VGK Complex antibody-positive encephalitis are major immune-mediated categories. It is more common in women and younger patients. | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
Encephalitis due to any cause has a yearly incidence of 2–3 per 100,000 in northern Europe, which is half the incidence of multiple sclerosis (4–8 per 100,000 annually). | |||
*While 40% of cases are infectious and 40% are attributable to unknown causes, at least 20% are immune-mediated, with anti-NMDA-receptor encephalitis (4%) and VGK Complex antibody-positive encephalitis (3%) constituting the major categories. | |||
*The condition is more prevalent among women (81%) and younger patients (37% 18 years, 95% 45 years); however, in the age categories younger than 12 years and older than 45 years, the disease is more prevalent among men nearly half of patients are male. | |||
==References== | ==References== | ||
| Line 12: | Line 19: | ||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
<ref name="pmid21331529">{{cite journal| author=Irani SR, Vincent A| title=NMDA receptor antibody encephalitis. | journal=Curr Neurol Neurosci Rep | year= 2011 | volume= 11 | issue= 3 | pages= 298-304 | pmid=21331529 | doi=10.1007/s11910-011-0186-y | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21331529 }} </ref> | |||
<ref name="pmid25340058">{{cite journal| author=Hacohen Y, Absoud M, Hemingway C, Jacobson L, Lin JP, Pike M | display-authors=etal| title=NMDA receptor antibodies associated with distinct white matter syndromes. | journal=Neurol Neuroimmunol Neuroinflamm | year= 2014 | volume= 1 | issue= 1 | pages= e2 | pmid=25340058 | doi=10.1212/NXI.0000000000000002 | pmc=4202680 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25340058 }} </ref> | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 08:18, 13 May 2023
|
Anti-NMDA receptor encephalitis Microchapters |
|
Differentiating Anti-NMDA receptor encephalitis from Other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Anti-NMDA receptor encephalitis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Anti-NMDA receptor encephalitis epidemiology and demographics |
|
FDA on Anti-NMDA receptor encephalitis epidemiology and demographics |
|
CDC on Anti-NMDA receptor encephalitis epidemiology and demographics |
|
Anti-NMDA receptor encephalitis epidemiology and demographics in the news |
|
Blogs on Anti-NMDA receptor encephalitis epidemiology and demographics |
|
Directions to Hospitals Treating Anti-NMDA receptor encephalitis |
|
Risk calculators and risk factors for Anti-NMDA receptor encephalitis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; AE Dheeraj Makkar, M.D.[2]
Overview
Encephalitis has an annual incidence of 2-3 per 100,000, with 40% being infectious, 40% of unknown cause, and 20% immune-mediated. Anti-NMDA receptor encephalitis and VGK Complex antibody-positive encephalitis are major immune-mediated categories. It is more common in women and younger patients.
Epidemiology and Demographics
Encephalitis due to any cause has a yearly incidence of 2–3 per 100,000 in northern Europe, which is half the incidence of multiple sclerosis (4–8 per 100,000 annually).
- While 40% of cases are infectious and 40% are attributable to unknown causes, at least 20% are immune-mediated, with anti-NMDA-receptor encephalitis (4%) and VGK Complex antibody-positive encephalitis (3%) constituting the major categories.
- The condition is more prevalent among women (81%) and younger patients (37% 18 years, 95% 45 years); however, in the age categories younger than 12 years and older than 45 years, the disease is more prevalent among men nearly half of patients are male.
References
[1] [2] Template:WH Template:WS
- ↑ Irani SR, Vincent A (2011). "NMDA receptor antibody encephalitis". Curr Neurol Neurosci Rep. 11 (3): 298–304. doi:10.1007/s11910-011-0186-y. PMID 21331529.
- ↑ Hacohen Y, Absoud M, Hemingway C, Jacobson L, Lin JP, Pike M; et al. (2014). "NMDA receptor antibodies associated with distinct white matter syndromes". Neurol Neuroimmunol Neuroinflamm. 1 (1): e2. doi:10.1212/NXI.0000000000000002. PMC 4202680. PMID 25340058.